Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Consolidated Net Income (2016 - 2025)

Collegium Pharmaceutical has reported Consolidated Net Income over the past 10 years, most recently at $17.0 million for Q4 2025.

  • Quarterly results put Consolidated Net Income at $17.0 million for Q4 2025, up 35.31% from a year ago — trailing twelve months through Dec 2025 was $62.9 million (down 9.13% YoY), and the annual figure for FY2025 was $62.9 million, down 9.13%.
  • Consolidated Net Income for Q4 2025 was $17.0 million at Collegium Pharmaceutical, down from $31.5 million in the prior quarter.
  • Over the last five years, Consolidated Net Income for COLL hit a ceiling of $72.8 million in Q2 2021 and a floor of -$25.0 million in Q4 2021.
  • Median Consolidated Net Income over the past 5 years was $12.3 million (2024), compared with a mean of $11.3 million.
  • Peak annual rise in Consolidated Net Income hit 7577.45% in 2021, while the deepest fall reached 459.79% in 2021.
  • Collegium Pharmaceutical's Consolidated Net Income stood at -$25.0 million in 2021, then surged by 71.24% to -$7.2 million in 2022, then skyrocketed by 543.67% to $31.9 million in 2023, then crashed by 60.75% to $12.5 million in 2024, then soared by 35.31% to $17.0 million in 2025.
  • The last three reported values for Consolidated Net Income were $17.0 million (Q4 2025), $31.5 million (Q3 2025), and $12.0 million (Q2 2025) per Business Quant data.